Zastrozhin Mikhail, Skryabin Valentin, Petukhov Aleksey, Pankratenko Elena, Pozdniakov Sergei, Ivanchenko Valentina, Horyaev Denis, Vlasovskih Roman, Bryun Evgeny, Sychev Dmitry
University of California, San Francisco, CA, USA.
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
J Psychopharmacol. 2022 Oct;36(10):1146-1150. doi: 10.1177/02698811221112939. Epub 2022 Jul 21.
Selective serotonin reuptake inhibitors have a common and increasing use for the treatment of patients diagnosed with depressive disorders. Some of them do not respond adequately to therapy,
The objective of our study was to evaluate the effect of polymorphism of on the concentration/dose ratio of paroxetine.
The study enrolled 267 patients with depressive episode (average age, 40.3 ± 14.3 years). Therapy included paroxetine in an average daily dose of 25.1 ± 9.5 mg per day. The efficacy and safety rates of treatment were evaluated using the international psychometric scales. For genotyping, we performed the real-time polymerase chain reaction. Therapeutic drug monitoring has been performed using high-performance liquid chromatography mass spectrometry (HPLC-MS/MS).
Our study revealed the statistically significant results in terms of treatment efficacy (Hamilton Depression Rating Scale scores): () 2.0 [1.0; 3.0] and () 4.0 [2.0; 5.0], < 0.001; meanwhile, no statistically significant results were obtained for the safety profile (Udvalg for Kliniske Undersogelser (UKU) Scale scores): () 3.0 [2.0; 3.0] and () 3.0 [3.0; 4.0], = 0.056. We revealed the statistically significant results for the concentration/dose ratio of paroxetine in patients with different genotypes: () 2.803 [2.154; 4.098] and () 5.098 [3.560; 7.241], < 0.001.
The effect of genetic polymorphism on the efficacy profile of paroxetine was demonstrated in a group of 267 patients with depressive disorder.
选择性5-羟色胺再摄取抑制剂在治疗被诊断为抑郁症的患者中使用普遍且日益增加。其中一些患者对治疗反应不佳。
我们研究的目的是评估[此处原文缺失具体基因名称]基因多态性对帕罗西汀浓度/剂量比的影响。
该研究纳入了267例抑郁发作患者（平均年龄40.3±14.3岁）。治疗采用帕罗西汀，平均每日剂量为25.1±9.5毫克/天。使用国际心理测量量表评估治疗的疗效和安全性。进行基因分型时，我们采用了实时聚合酶链反应。使用高效液相色谱质谱联用仪（HPLC-MS/MS）进行治疗药物监测。
我们的研究在治疗疗效方面（汉密尔顿抑郁量表评分）得出了具有统计学意义的结果：（[此处原文缺失具体分组信息1]）2.0[1.0；3.0]和（[此处原文缺失具体分组信息2]）4.0[2.0；5.0]，P<0.001；同时，在安全性方面（临床检查委员会（UKU）量表评分）未得出具有统计学意义的结果：（[此处原文缺失具体分组信息1]）3.0[2.0；3.0]和（[此处原文缺失具体分组信息2]）3.0[3.0；4.0]，P=0.056。我们发现不同基因型患者的帕罗西汀浓度/剂量比具有统计学意义的结果：（[此处原文缺失具体分组信息1]）2.803[2.154；4.098]和（[此处原文缺失具体分组信息2]）5.098[3.560；7.241]，P<0.001。
在一组267例抑郁症患者中证明了[此处原文缺失具体基因名称]基因多态性对帕罗西汀疗效的影响。
